Screening Epoch Disposition eCRF

Slides:



Advertisements
Similar presentations
Susan Boynton, VP, Global Regulatory Affairs, Shire
Advertisements

UC5:Assigning of Epoch after treatment discontinuation (NS)
Focused on Pulmonology and Hepatology
John Naim, PhD Director Clinical Trials Research Unit
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Discontinuing Treatment and not for Resuscitation.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Gil Harari Statistical considerations in clinical trials
1 FDA Review of NDA Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.
Primary Care Trigger Tool Manaia Health PHO Linda Holman Quality Leader.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
Data Management in Clinical Trials. E-CRF design / P-CRF Data entryData validation Data import Clinical coding DATABASE CLOSURE Database Closure Documents.
MFAS Mathematics Formative Assessment System We shall be using tasks from MFAS.
ITT populations EASTERN: n=216 WESTERN: n=234 Randomized to asenapine and received  1 treatment EASTERN: n=241 WESTERN: n=244 Randomized to olanzapine.
July 25 th 2014 Cenduit – new study drug discontinuation forms.
Investigator’s Meeting
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.
General Instructions for CRF 3 Rev H To be completed at each follow up visit Patient Identification and Group Date of Visit Assessment performed physician.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
How Good is Your SDTM Data? Perspectives from JumpStart Mary Doi, M.D., M.S. Office of Computational Science Office of Translational Sciences Center for.
Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine.
Design of Case Report Forms
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis 
Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation
Reporting Student Progress
Role of The Physical Therapist in Critical Inquiry
Safety Reporting Carrie Bayliss.
Capture / Recapture Applying Ratios to Probability
Clinicaltrials.gov Update
Fig. 1. Study enrollment and disposition of participants
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Harrison CN et al. Proc ASH 2015;Abstract 59.
Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.
The Nurse View.
Health Strategies Group
PCSK9 Inhibitors Post-CVOTs
Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
An Endocrinology Clinic in Dyslipidemia
Aligning Estimands and Estimators – A Case Study Sept 13, 2018 Elena Polverejan Vladimir Dragalin Quantitative Sciences Janssen R&D, Johnson & Johnson.
Phase 2 Treatment Naïve Injection Drug Use
In-Depth Report from Optimizing Data Standards Working Group
SERIOUS ADVERSE EVENTS REPORTING
Aiying Chen, Scott Patterson, Fabrice Bailleux and Ehab Bassily
This presentation has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational purposes.
Role of The Physical Therapist in Critical Inquiry
A Time for Change for Managing Patients With VTE Who Have Cancer
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection 
Switch to LPV/r monotherapy
E-CRF Overview Oracle® Clinical Remote Data Capture Training (Version 4.6 HTML) e-CRF Completion John McDonach Manager CDM, PPD.
Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.
Streamlined Data Collection
Best Practices for Data Collection Instructions
Flow of Patients Through the Trial
Flow of Patients Through Trial
What Do We Know About Estimators for the Treatment Policy Estimand
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials  Philip Darney, M.D., Ashlesha Patel,
Patient disposition, weeks 24–128.
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma  Bob Lanier, MD, Tracy Bridges,
Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations.
How Should We Select and Define Trial Estimands
Jared Christensen and Steve Gilbert Pfizer, Inc July 29th, 2019
Translating Data From Trial to Practice
Presentation transcript:

Screening Epoch Disposition eCRF

Treatment/Run-in/Follow-up Epoch Disposition eCRF

Study Treatment Disposition eCRF

eCRF Completion Instructions for End of Epoch disposition At the end of each epoch, a Disposition event CRF must be completed. These CRFs collect information on the subject status – whether they completed and if the subject discontinued the primary reason for discontinuation. It is important to consider whether the subject discontinued for reasons related to safety (e.g. Adverse Experiences, Death) or reasons related to efficacy (e.g. Lack of Efficacy, Disease Progression, No Longer Requires Treatment ) If the subject is discontinuing for reasons NOT related to efficacy or safety then indicate one of the other available reasons (list provide below). These other reasons must not be used when the underlying reason is related to Adverse Events or Lack of Efficacy.

eCRF Completion Instructions for End of Study Treatment eCRF This CRF is only needed in trials where the End of Study Treatment is different from End of <Treatment> Epoch completion, such as Outcome driven trials, where the End of Study Treatment needs to be captured outside of the End of Study disposition page. In these studies both disposition pages, i.e. End of Study Treatment and End of <Treatment> Epoch completion will be needed in the <Treatment> Epoch. Study teams must decide if this page is needed within the trial. This CRF should be completed when:   A subject discontinues study treatment prior to the end of the epoch. A subject completes the study treatment in the epoch.